It's All in the Genes  by unknown
Neuron
EditorialIt’s All in the GenesIn this issue of Neuron, we present a series of Perspectives and Reviews on neurogenetics. These commissioned Reviews highlight
some of the ways in which new genetic and genomic approaches are changing the way we think about how the brain develops and
functions, in the context of both disease and ‘‘normal’’ function. Neurogenetics is such a rich research area that we could not have
hoped to cover the full spectrum of this exciting field in one issue ofNeuron. Our aim was to highlight a range of research approaches
and topics and to spotlight some of the conceptual themes that have emerged in recent years.
In their Overview, StephenWarren and Huda Zoghbi reflect on the current state of neurogenetics research and discuss future chal-
lenges and opportunities for the field. Over the past two decades, there has been an explosion of neurogenetic research. The local-
ization of the gene for Huntington disease to chromosome 4 in 1983 (and, subsequently, the cloning of the gene in 1993) heralded the
dawn of the modern era for neurogenetics research, and the eighties and nineties were a time when a number of prominent disease
genes were first identified by positional cloning strategies. To point to a few notable examples: APP was found to be associated with
Alzheimer disease (1987), FMR1 was identified as the gene for fragile X syndrome (1991), alpha-synuclein was identified as mutated
in familial forms of Parkinson disease (1999), and MeCP2 was shown to be the gene mutated in Rett syndrome (1999).
Now, almost a decade since release of the first drafts of the human genome sequence in 2001, new high-throughput genomic
technologies and analytical approaches are helping researchers gain traction on the genes and genetic architecture that
contribute to a large number of genetic disorders of the brain and nervous system. We have learned a lot about individual genes
and pathways, and slowly but surely a clearer map is emerging that starts to place these pathways within the context of larger
neurobiological systems. Genetics have brought us a wealth of information, but ultimately, gene discovery alone is not going to
be enough and there is a pressing need in the field to integrate this genetic information with a better understanding of the under-
lying biology. This will require an integration of approaches, from molecular and cellular techniques for probing the mechanistic
functions of these genes and pathways to circuit-, systems-, and cognitive-level approaches for assessing the roles of these
genes within a functional context.
The good news is that the field is well poised for this challenge. Animal models and a broad range of new genetic and molecular
tools to manipulate gene function in vivo in the intact circuitry and in the context of behavior offer opportunities to test how alterations
in genotype affect phenotype. At the same time, cognitive neuroscience approaches in humans, both in unaffected and in disease
populations, are providing amore nuanced understanding of the range of neurocognitive phenotypes, which allows for better assess-
ment and stratification of populations and, in turn, brings us nearer to closing the loop between genotype and phenotype.
In addition to these Reviews and Perspectives, the issue also contains a collection of NeuroViews that look at the broader impli-
cations and practices associated with neurogenetics research. Elana Brief and Judith Illes write about the challenges of consent and
confidentiality as related to cultural values of different populations and how this impacts neurogenetic research. Xandra Breakefield
and Miguel Sena-Esteves review the possibilities for gene therapeutic approaches for disorders of the nervous system, from both
a practical and an ethical perspective.
Human genetics and genomic research carries a variety of challenges, not the least of these is that many, if not most, neurological
and psychiatric disorders are genetically complex. Therefore, to gain appropriate statistical power requires very large numbers of
subjects, including both affected individuals and appropriate controls. Likewise, many of these neurological and psychiatric disor-
ders are also clinically very complicated, and to be able to compare and replicate data across populations, rigorous and detailed
clinical assessments are needed. These challenges have necessitated a different kind of research organization than the typical indi-
vidual laboratory-based approach. Three NeuroViews look at how large-scale collaborations and consortia-based approaches are
impacting neurogenetics research. Patrick Sullivan provides an overview of the Psychiatric GWAS Consortium (PGC) and its history
and function within the psychiatric genetics community. The autism research community has been particularly successful at
leveraging the commitment and determination of families with autism to develop shared resources and repositories for patient
samples and data. Clara Lajonchere, from Autism Speaks, writes about the Autism Genetic Research Exchange (AGRE), a project
that was initially spearheaded by a consortium of parents, researchers, and clinicians under the auspices of the autism advocacy
group Cure Autism Now (CAN) to provide a repository of well-characterized patient and family data and biological samples, for
use by the research community at large. Gerald Fischbach andCatherine Lord, of the Simons Foundation, discuss a similar approach
taken by the Simons Foundation Autism Research Initiative (SFARI). The Simons Simplex Collection (SSC) was created as repository
of carefully evaluated data and samples from a large number of what are known as ‘‘simplex’’ families—that is, families with one child
with autism—in order to understand the origin of sporadic cases of autism and uncover rare genetic variants. The PGC, AGRE, and
SSC are examples of a new kind of a collaborative research approach involving a combination of public-private partnerships and the
sharing of resources, data, and information in a manner that is efficient, well-managed, and broadly accessible to the research
community.Neuron 68, October 21, 2010 ª2010 Elsevier Inc. 163
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EditorialThe Neuron Editors would like to thank all of the authors, as well as the reviewers and other experts who provided feedback on the
Reviews and topics in this special issue. We are extremely grateful for all of the time and thought that these authors put into their
Reviews. We hope that these Reviews will stimulate broad interest in this exciting field and discussion throughout the neuroscience
research community. The field of neurogenetics promises to continue to bring exciting and potentially unexpected insights into our
understanding of neurobiology, and we look forward to seeing what the next 20 years will bring.
This special issue will be featured at the Society for Neuroscience meeting in San Diego (SFN exhibitor booth #1200), as well as the
American Society for Human Genetics meeting (ASHG exhibitor booth #1228) in Washington, D.C., and we invite you to stop by
the Cell Press-Elsevier exhibitor booth to pick up a free copy of this special issue.
To close we would like to say a few words about the cover art, which is an adaptation of an original painting, entitled Blood
Quantum, by Kyle Ethan Fischer. Mr. Fischer is an artist of both European and First Nation descent whose artwork is often influenced
by imagery from biological sciences. We selected this painting because the image ideally represents a number of the themes in this
issue and in the neurogenetics field overall. This painting depicts the benefits that genetics brings to our understanding of human
neurobiology and to potential treatments of psychiatric and neurological disorders, but it also highlights the internal turmoil that indi-
viduals may face once they have gained knowledge of their own neurogenetic makeup. More information on this and other original
artwork by this artist can be found at his website, www.kyleethanfischer.com.164 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.
